NCT00442572View on ClinicalTrials.gov

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 3, 2006

Primary Completion Date

April 23, 2012

Study Completion Date

April 23, 2012

Conditions
Hepatitis B, Chronic
Interventions
DRUG

PEGASYS [peginterferon alfa-2a]

There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.

Trial Locations (1)

1612

Mhat St. Ivan Rilski; Clinic of Gastroenterology, Sofia

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00442572 - SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB). | Biotech Hunter | Biotech Hunter